Clinical Trial Results:
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in
Patients Not Eligible for Intensive Induction Chemotherapy
|
Summary
|
|
EudraCT number |
2015-001790-41 |
Trial protocol |
BE DE GB ES FR PL HU GR IT |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 May 2026
|
First version publication date |
02 May 2026
|
Other versions |
|
Summary report(s) |
EU CTIS Redirect |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.